ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases
Authors
Keywords
-
Journal
Future Oncology
Volume -, Issue -, Pages -
Publisher
Future Medicine Ltd
Online
2019-05-10
DOI
10.2217/fon-2019-0180
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial
- (2017) Chris Twelves et al. EUROPEAN JOURNAL OF CANCER
- Brain Metastases in Newly Diagnosed Breast Cancer
- (2017) Allison M. Martin et al. JAMA Oncology
- Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration
- (2016) S. Kenneth Sy et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer
- (2016) Chris Twelves et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Targeted Therapies for Brain Metastases from Breast Cancer
- (2016) Vyshak Venur et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases
- (2016) Paul D. Brown et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Brain metastasis in breast cancer: a comprehensive literature review
- (2016) Rezvan Rostami et al. JOURNAL OF NEURO-ONCOLOGY
- Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial
- (2016) Javier Cortés et al. SpringerPlus
- Breast Cancer Subtypes Predispose the Site of Distant Metastases
- (2015) Abha Soni et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer
- (2015) Chris E. Adkins et al. BMC CANCER
- Activity of T-DM1 in Her2-positive breast cancer brain metastases
- (2015) Rupert Bartsch et al. CLINICAL & EXPERIMENTAL METASTASIS
- Brain Metastasis and Response to Ado-Trastuzumab Emtansine: A Case Report and Literature Review
- (2015) Richa Kalsi et al. Clinical Breast Cancer
- Phase 3 Trials of Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for 1 to 4 Brain Metastases: Individual Patient Data Meta-Analysis
- (2015) Arjun Sahgal et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma
- (2015) Seema Nagpal et al. JOURNAL OF NEURO-ONCOLOGY
- Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial
- (2015) Javier Cortés et al. LANCET ONCOLOGY
- Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial
- (2015) Edith A Perez et al. LANCET ONCOLOGY
- Response assessment criteria for brain metastases: proposal from the RANO group
- (2015) Nancy U Lin et al. LANCET ONCOLOGY
- The controversy surrounding the use of whole-brain radiotherapy in brain metastases patients
- (2015) M. P. Mehta NEURO-ONCOLOGY
- Point/Counterpoint: Stereotactic radiosurgery without whole-brain radiation for patients with a limited number of brain metastases: the current standard of care?
- (2015) Arjun Sahgal NEURO-ONCOLOGY
- Prognostic factors and survival of patients with brain metastasis from breast cancer who underwent craniotomy
- (2015) José Pablo Leone et al. Cancer Medicine
- Metastatic breast cancer subtypes and central nervous system metastases
- (2014) C. Aversa et al. BREAST
- TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases
- (2014) Carey Anders et al. BREAST CANCER RESEARCH AND TREATMENT
- Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models
- (2014) Ute Hoch et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: An overview of the literature
- (2014) Giuseppe Lombardi et al. CANCER TREATMENT REVIEWS
- Chemotherapy and biological treatment options in breast cancer patients with brain metastasis: an update
- (2014) Cagatay Arslan et al. EXPERT OPINION ON PHARMACOTHERAPY
- Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline
- (2014) Naren Ramakrishna et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II trial of patupilone in patients with brain metastases from breast cancer
- (2014) D. M. Peereboom et al. NEURO-ONCOLOGY
- Breast cancer brain metastases: a review of the literature and a current multidisciplinary management guideline
- (2013) M. J. Gil-Gil et al. Clinical & Translational Oncology
- Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network
- (2012) Nancy U. Lin et al. CANCER
- A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etirinotecan Pegol in Patients with Refractory Solid Tumors
- (2012) G. S. Jameson et al. CLINICAL CANCER RESEARCH
- Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy
- (2012) J.P.M. Ayoub et al. Current Oncology
- Breast Cancer Resistance Protein and P-Glycoprotein in Brain Cancer: Two Gatekeepers Team Up
- (2012) Sagar Agarwal et al. CURRENT PHARMACEUTICAL DESIGN
- Chemotherapy-Resistant Metastatic Breast Cancer
- (2012) Carrie Marquette et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment
- (2012) Agnes V Tallet et al. Radiation Oncology
- A meta-analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients presenting with a limited number of brain metastases
- (2011) May Tsao et al. CANCER
- A Phase II Study of Sagopilone (ZK 219477; ZK-EPO) in Patients With Breast Cancer and Brain Metastases
- (2011) Rachel A. Freedman et al. Clinical Breast Cancer
- Effect of Tumor Subtype on Survival and the Graded Prognostic Assessment for Patients With Breast Cancer and Brain Metastases
- (2011) Paul W. Sperduto et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
- (2011) Paul W. Sperduto et al. JOURNAL OF CLINICAL ONCOLOGY
- Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases
- (2010) Anna Niwińska et al. CANCER
- Heterogeneous Blood-Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer
- (2010) P. R. Lockman et al. CLINICAL CANCER RESEARCH
- Metastatic Behavior of Breast Cancer Subtypes
- (2010) Hagen Kennecke et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study
- (2010) Martin Kocher et al. JOURNAL OF CLINICAL ONCOLOGY
- Adaptive increase in sample size when interim results are promising: A practical guide with examples
- (2010) Cyrus R. Mehta et al. STATISTICS IN MEDICINE
- Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT)
- (2009) A. Niwinska et al. ANNALS OF ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search